Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

NCT04699461 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Administrative decision (not due to safety reason)

Conditions

Relapsed Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions

DRUG: Loncastuximab Tesirine
DRUG: Idelalisib

Sponsor

ADC Therapeutics S.A.